

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5132618

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
IGM BIOSCIENCES A/S	08/21/2018

RECEIVING PARTY DATA

Name:	IGM BIOSCIENCES, INC.
Street Address:	325 E. MIDDLEFIELD RD
City:	MOUNTAIN VIEW
State/Country:	CALIFORNIA
Postal Code:	94043

PROPERTY NUMBERS Total: 34

Property Type	Number
Application Number:	62128284
Application Number:	15554301
Application Number:	62149460
Application Number:	15566485
Application Number:	62137881
Application Number:	15560905
Application Number:	62105323
Application Number:	15638748
Application Number:	15544873
Application Number:	62364763
Application Number:	62364762
Application Number:	62364760
Application Number:	62364758
Application Number:	62483087
Application Number:	62635033
Application Number:	62637186
Application Number:	61874277
Application Number:	61874284
Application Number:	14916166
Application Number:	61937984

PATENT

Property Type	Number
Application Number:	15117432
Application Number:	61974738
Application Number:	15301366
Application Number:	15452616
Application Number:	62235486
Application Number:	15764870
Application Number:	62235518
Application Number:	15764859
Application Number:	62333643
Application Number:	60625398
Application Number:	11267935
Application Number:	13770619
Application Number:	61633330
Application Number:	13763398

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2022869629

Email: megan.remer@fisherbroyles.com

Correspondent Name: ELIZABETH J. HAANES

Address Line 1: FISHERBROYLES LLP

Address Line 2: 945 EAST PACES FERRY ROAD NE, SUITE 200

Address Line 4: ATLANTA, GEORGIA 30328

ATTORNEY DOCKET NUMBER: 09789.0008

NAME OF SUBMITTER: ELIZABETH J. HAANES

SIGNATURE: /Elizabeth J. Haanes, Reg. No.: 42,613/

DATE SIGNED: 09/10/2018

Total Attachments: 11

source=Executed-assignment-AS-to-INC#page1.tif
source=Executed-assignment-AS-to-INC#page2.tif
source=Executed-assignment-AS-to-INC#page3.tif
source=Executed-assignment-AS-to-INC#page4.tif
source=Executed-assignment-AS-to-INC#page5.tif
source=Executed-assignment-AS-to-INC#page6.tif
source=Executed-assignment-AS-to-INC#page7.tif
source=Executed-assignment-AS-to-INC#page8.tif
source=Executed-assignment-AS-to-INC#page9.tif
source=Executed-assignment-AS-to-INC#page10.tif
source=Executed-assignment-AS-to-INC#page11.tif

ASSIGNMENT OF PATENT RIGHTS

This Assignment, is effective 21 August 2018 between IGM Biosciences A/S i likvidation and IGM Biosciences, Inc.

WHEREAS IGM Biosciences A/S i likvidation (company registration number (CVR no.) 39 12 36 49), a corporation of Denmark, having its principal office and place of business at Haldor Topsøes Allé 1, 2800 Kgs. Lyngby, Denmark ("ASSIGNOR"), owns all right, title, and interest in and to the patents and patent applications set forth in **Schedule 1**, and the inventions disclosed or claimed therein (all of the foregoing collectively the "Patent Rights"); and

WHEREAS IGM Biosciences, Inc., a corporation of Delaware, having its principal office and place of business at 325 E. Middlefield Rd, Mountain View, CA 94043, USA ("ASSIGNEE"), is desirous of acquiring ASSIGNOR's entire right, title, and interest in and to said Patent Rights.

THEREFORE, in consideration of the sum of one United States dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby assigns to ASSIGNEE its entire right, title and interest in and to said Patent Rights and improvements as the same are disclosed in said Patent Rights, in and to any and all letters patent(s) and applications filed therefor, including provisionals, non-provisionals, divisionals, continuations, continuations-in-part, reissues, reexaminations, and extensions to be obtained therefor in the United States and all foreign countries, including all priority rights and all rights to claim priority; and ASSIGNOR further agrees to cooperate with ASSIGNEE hereunder in the obtaining and sustaining of any and all such Letters Patent(s) as ASSIGNEE may desire to apply for.

The Commissioner of Patents or other proper official is hereby authorized and requested to issue said Patent Rights to ASSIGNEE in accordance with this Assignment.

ASSIGNOR hereby authorizes and requests the attorneys of record in said Patent Rights to insert in this Assignment the serial number, filing date, and date of execution of any items of said Patent Rights for the purposes of recording this Assignment.

For said consideration, ASSIGNOR hereby agrees, upon the request of ASSIGNEE, to execute any provisional, non-provisional, divisional, continuation, continuation-in-part, or substitute application for said Patent Rights, and any application or patent claiming priority to any of the Patent Rights or to which the Patent Rights claim priority, and any oath or affidavit relating thereto, and any application for the reissue or extension of any letters patent that may be granted upon said Patent Rights, and, in the event of any application or letters patent of the Patent Rights becoming involved in an interference, opposition, post-grant review, inter-partes review, litigation, or any other proceeding in the United States or any foreign country, to cooperate to the best of its ability in the matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof. ASSIGNOR agrees to perform, upon request, any affirmative acts to obtain letters patents from the Patent Rights and vest in ASSIGNEE all rights therein, whereby said Patent Rights will be held and enjoyed by ASSIGNEE, to the full end of the term for which said Patent Rights may be granted as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this Assignment had not been made.


And for said consideration, ASSIGNOR hereby assigns to ASSIGNEE its entire right, title and interest in said Patent Rights for all foreign countries, including all priority rights, and agrees to execute, at the request of ASSIGNEE, all documents in connection with any application for foreign letters patent within the Patent Rights.

This Assignment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Assignment by facsimile or in electronic (i.e., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart of this Assignment.

IN WITNESS WHEREOF, I have hereunto set my hand the 21 day of AUGUST.

ASSIGNOR:

IGM Biosciences A/S likvidation

By: 

Name: Michael Nørremark
Title: Liquidator

SCHEDULE 1

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-04-15	2016249404		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-04-15	29883024		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	China	Application	2016-04-15	20166035419.8		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-04-15	16790944.1		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Hong Kong	Application	2016-04-27	16105481.5		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-04-15	2017-554329		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-04-15	PCT/US2016/027879		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-04-17	62145460		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-04-15	15565 485		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-03-25	2016238246		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-03-25	2880751		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	China	Application	2016-02-25	201690029923.0		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-03-25	16769812.5		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-03-25	2017-549723		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Korea, Republic of (KR)	Application	2016-03-25	16-2017-7036451		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-03-25	PCT/US2016/024346		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-03-25	62143788.1		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-03-25	15560905		

TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-01-20	2016209324		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-01-20	2,972,990		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	China	Application	2016-01-20	201863005321X		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-01-20	16740986.7		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Hong Kong	Application	43137	18101797.3		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	India	Application	2016-01-20	201737026527		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Israel	Application	2016-01-20	353054		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-01-20	2017-556796		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Korea, Republic of (KR)	Application	2016-01-20	10-2017-7022773		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	New Zealand	Application	2016-01-20	722922		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-01-20	PCT/US2016/014153		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Singapore	Application	2016-01-20	11201705116S		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-01-20	627105323		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-01-20	15/544,873		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	United States of America	Granted	2017-05-30	15/636746	2018-04-10	9,938,347
CD28 BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-03-04	2016228066		
CD28 BINDING MOLECULES AND USES THEREOF	Brazil	Application	2016-03-04	BR112017018941-0		

CD20 BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-03-04	2,978,324		
CD20 BINDING MOLECULES AND USES THEREOF	China	Application	2016-03-04	201860028078.8		
CD20 BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-03-04	167369586.7		
CD20 BINDING MOLECULES AND USES THEREOF	Hong Kong	Application	2016-01-29	18101348.7		
CD20 BINDING MOLECULES AND USES THEREOF	India	Application	2016-03-04	30177033549		
CD20 BINDING MOLECULES AND USES THEREOF	Israel	Application	2016-03-04	264923		
CD20 BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-03-04	2017-546881		
CD20 BINDING MOLECULES AND USES THEREOF	Korea, Republic of (KR)	Application	2016-03-04	10-2017-7027638		
CD20 BINDING MOLECULES AND USES THEREOF	New Zealand	Application	2016-03-04	705607		
CD20 BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-03-04	PCT/US2016/020920		
CD20 BINDING MOLECULES AND USES THEREOF	Singapore	Application	2016-03-04	11201707144V		
CD20 BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-03-04	62/128284		
CD20 BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-03-04	19/554,301		
MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-20	PCT/US2017/043185		
MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364762		
MULTIMERIC GITR BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-20	PCT/US2017/043186		
MULTIMERIC GITR BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364762		
MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-19	PCT/US2017/042931		
MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364763		
MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-18	PCT/US2017/042933		
MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364758		
MODIFIED HUMAN IGM CONSTANT REGIONS FOR MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION	United States of America	Expired	2017-04-07	62/483087		

MODIFIED HUMAN IGM CONSTANT REGIONS FOR MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION	Patent Cooperation Treaty	Application	2018-04-09	PCT/US2018/025474		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	Australia	Application	2014-09-04	2014332458		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	Brazil	Application	2014-09-04	BR112016004768-0		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	Canada	Application	2014-09-04	2,922,830		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	China	Application	2014-09-04	201490051238.5		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	European Patent	Application	2014-09-04	14766828.3		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	India	Application	2014-09-04	201647910705		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	Japan	Application	2014-09-04	2016-540383		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	Korea, Republic of (KR)	Application	2014-09-04	10-2016-7007082		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	Patent Cooperation Treaty	Closed	2014-09-04	PCT/US2014/054079		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IGM ANTIBODIES	United States of America	Application	2014-09-04	14/916,168		
BINDING MOLECULES	United States of America	Expired	2013-09-05	61/674,277		
BINDING MOLECULES	United States of America	Expired	2013-09-05	61/674,284		
IGA MULTI-SPECIFIC BINDING MOLECULES	Australia	Application	2015-02-10	2015213553		
IGA MULTI-SPECIFIC BINDING MOLECULES	Brazil	Application	2015-02-10	BR112016016313-4		
IGA MULTI-SPECIFIC BINDING MOLECULES	Canada	Application	2015-02-10	2,958,191		
IGA MULTI-SPECIFIC BINDING MOLECULES	China	Application	2015-02-10	201568007962.9		
IGA MULTI-SPECIFIC BINDING MOLECULES	European Patent	Application	2015-02-10	16706611.9		
MULTI SPECIFIC IGA BINDING MOLECULES	Hong Kong	Application	2016-03-11	17104620.1		
IGA MULTI-SPECIFIC BINDING MOLECULES	India	Application	2015-02-10	201647030490		

IGA MULTI-SPECIFIC BINDING MOLECULES	Japan	Application	2015-02-10	2015-568491			
IGA MULTI-SPECIFIC BINDING MOLECULES	Korea, Republic of (KR)	Application	2015-02-10	10-2015-7024677			
IGA MULTI-SPECIFIC BINDING MOLECULES	Patent Cooperation Treaty	Closed	2015-02-10	PCT/US2015/015288			
IGA MULTI-SPECIFIC BINDING MOLECULES	United States of America	Application	2015-02-10	15/117,432			
MULTI SPECIFIC IGA BINDING MOLECULES	United States of America	Expired	2014-02-10	61/937,984			
MODIFIED J-CHAIN	Australia	Application	2015-04-02	2015246595			
MODIFIED J-CHAIN	Brazil	Application	2015-04-02	BR112016022841-3			
MODIFIED J-CHAIN	Canada	Application	2015-04-02	2,844,647			
MODIFIED J-CHAIN	China	Application	2015-04-02	201530018543.1			
MODIFIED J-CHAIN	European Patent	Application	2015-04-02	15718304.7			
MODIFIED J-CHAIN	Hong Kong	Application	42218	1710711			
MODIFIED J-CHAIN	India	Application	2015-04-02	201647037003			
MODIFIED J-CHAIN	Israel	Application	2015-04-02	246151			
MODIFIED J-CHAIN	Japan	Application	2015-04-02	2015-560487			
MODIFIED J-CHAIN	Korea, Republic of (KR)	Application	2015-04-02	10-2016-7030462			
MODIFIED J-CHAIN	Mexico	Application	2015-04-02	MX/a/2016/012880			
MODIFIED J-CHAIN	New Zealand	Application	2015-04-02	735556			
MODIFIED J-CHAIN	Patent Cooperation Treaty	Closed	2015-04-02	PCT/US2015/024149			
MODIFIED J-CHAIN	Russian Federation	Application	2015-04-02	2016141579			
MODIFIED J-CHAIN	Singapore	Application	2015-04-02	11201608194V			
MODIFIED J-CHAIN	South Africa	Application	2015-04-02	2016/05906			
MODIFIED J-CHAIN	United States of America	Granted	2017-03-07	15462816	2015-04-24	9,951,134	
MODIFIED J-CHAIN	United States of America	Application	2015-04-02	15/301,366			
MODIFIED J-CHAIN	United States of America	Expired	2014-04-03	61/974,738			
BINDING MOLECULES WITH MODIFIED J-CHAIN	China	Application	2016-09-30	201680089820.3			

BINDING MOLECULES WITH MODIFIED J-CHAIN	European Patent	Application	2016-09-30	16734322.5			
BINDING MOLECULES WITH MODIFIED J-CHAIN	Japan	Application	2018-03-30	2018-516820			
BINDING MOLECULES WITH MODIFIED J-CHAIN	United States of America	Application	2016-03-30	167784,870			
BINDING MOLECULES WITH MODIFIED J-CHAIN	Patent Cooperation Treaty	Closed	2016-03-30	PCT/US2016/065053			
BINDING MOLECULES WITH MODIFIED J-CHAIN	United States of America	Expired	2016-03-30	62/835,466			
BINDING MOLECULES WITH MODIFIED J-CHAIN	Australia	Application	2016-03-30	20163329197			
BINDING MOLECULES WITH MODIFIED J-CHAIN	Canada	Application	2016-03-30	2,999,284			
BINDING MOLECULES WITH MODIFIED J-CHAIN	China	Application	2016-03-30	201683068842.X			
BINDING MOLECULES WITH MODIFIED J-CHAIN	European Patent	Application	2016-03-30	16784320.0			
BINDING MOLECULES WITH MODIFIED J-CHAIN	Japan	Application	2016-03-30	2016-516668			
BINDING MOLECULES WITH MODIFIED J-CHAIN	United States of America	Application	2016-03-30	16774,859			
BINDING MOLECULES WITH MODIFIED J-CHAIN	Patent Cooperation Treaty	Closed	2016-03-30	PCT/US2016/055041			
BINDING MOLECULES WITH MODIFIED J-CHAIN	United States of America	Expired	2016-03-30	62/235,516			
ANTI-PD-L1 ANTIBODIES	Patent Cooperation Treaty	Application	2017-05-09	PCT/US2017/031791			
ANTI-PD-L1 ANTIBODIES	United States of America	Expired	2016-05-09	62/333,643			
Antibody Induced Cell Membrane Wounding	Austria	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Denmark	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	European Patent	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Finland	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Germany (Federal Republic of)	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Italy	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Netherlands	Granted	2005-11-04	05818169.4		2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Patent Cooperation Treaty	Closed	2005-11-04	PCT/US2005/039762			
Antibody Induced Cell Membrane Wounding	Sweden	Granted	2005-11-04	05818169.4		2015-08-19	1814913

Antibody Induced Cell Membrane Wounding	United States of America	Granted	2015-11-04	11/267,935	2013-02-19	9377435
Antibody Induced Cell Membrane Wounding	United States of America	Granted	2013-02-19	13/770,615	2016-10-04	9458241
Antibody Induced Cell Membrane Wounding	United States of America	Expired	2004-11-05	60/625,398		
CDIM Binding Proteins and Uses Thereof	Australia	Granted	2013-02-09	2013200903	2015-08-27	2013200903
CDIM Binding Proteins and Uses Thereof	Brazil	Application	2013-02-08	BR11201401945.9		
CDIM Binding Proteins and Uses Thereof	Canada	Application	2013-02-09	2863714		
CDIM Binding Proteins and Uses Thereof	China	Granted	2013-02-08	201380008615.X	2017-04-26	ZL201380008615.X
CDIM Binding Proteins and Uses Thereof	European Patent	Application	2013-02-08	13/713588.5		
CDIM Binding Proteins and Uses Thereof	Hong Kong	Application	2013-02-08	15105490.7		
CDIM Binding Proteins and Uses Thereof	India	Application	2013-02-08	1/781MUMNF/2014		
CDIM Binding Proteins and Uses Thereof	Japan	Application	2013-02-08	2014-558751		
CDIM Binding Proteins and Uses Thereof	Korea, Republic of (KR)	Application	2013-02-08	10-2014-7025110		
CDIM Binding Proteins and Uses Thereof	Mexico	Application	2013-02-08	MX/a/2014/009626		
CDIM Binding Proteins and Uses Thereof	Patent Cooperation Treaty	Closed	2013-02-08	PCT/US2013/025430		
CDIM Binding Proteins and Uses Thereof	Taiwan	Granted	2013-02-08	102105337	2017-11-21	8505064
CDIM Binding Proteins and Uses Thereof	United States of America	Granted	2013-02-08	13/763,398	2016-06-09	9408976
CDIM Binding Proteins and Uses Thereof	United States of America	Expired	2012-02-08	61/633,330		
USE OF A MULTIMERIC ANTIFOLATE BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER	United States of America	Application	2018-02-25	62/635,033		
1-CHAIN MUTATIONS THAT AFFECT IGM SERUM HALF-LIFE	United States of America	Application	2018-03-01	62/637,186		

PATENT

REEL: 047044 FRAME: 0950

RECORDED: 09/10/2018